Literature DB >> 17166234

Chronic Pseudomonas aeruginosa infection reduces surfactant levels by inhibiting its biosynthesis.

Yanghong Wu1, Zhiwei Xu, Florita C Henderson, Alan J Ryan, Timothy L Yahr, Rama K Mallampalli.   

Abstract

Chronic Pseudomonas aeruginosa infection, as occurs in cystic fibrosis, is associated with decreased surfactant phospholipid levels. To investigate mechanisms, we measured synthesis of dipalmitoylphosphatidylcholine (DPPC), the major surfactant phospholipid. Mice received an agarose bead slurry alone, or were infected with beads containing a clinical mucoid isolate of P. aeruginosa. Bacterial infection after 3 days resulted in a approximately 50% reduction in surfactant DPPC content versus control. These changes in surfactant were associated with co-ordinate reductions in mRNAs and immunoreactive levels for CTP: phosphocholine cytidylyltransferase (CCTalpha), the rate-regulatory enzyme required for DPPC synthesis. P. aeruginosa infection of murine lung epithelia decreased CCTalpha gene transcription without altering mRNA stability and by a mechanism other than release of a soluble extracellular inhibitor. Promoter deletional analysis revealed that P. aeruginosa activates a negative response element from -1019 to -799 bp of the CCTalpha proximal 5'-flanking region. Exposure of cells to a P. aeruginosa mutant strain producing alginate reduced CCTalpha promoter activity, whereas these effects were not observed in strains defective in alginate synthesis. Murine type II cells isolated from P. aeruginosa-infected CCTalpha promoter-beta-galactosidase transgenic mice exhibited significantly reduced CCT and beta-galactosidase enzyme activities versus control. Thus, a mucoid P. aeruginosa strain reduces mRNA synthesis of a key biosynthetic enzyme thereby decreasing levels of surfactant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17166234     DOI: 10.1111/j.1462-5822.2006.00852.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  8 in total

1.  Analysis of lipids from crude lung tissue extracts by desorption electrospray ionization mass spectrometry and pattern recognition.

Authors:  Franco Basile; Tamara Sibray; John T Belisle; Richard A Bowen
Journal:  Anal Biochem       Date:  2010-09-22       Impact factor: 3.365

Review 2.  Surfactant and its role in the pathobiology of pulmonary infection.

Authors:  Jennifer R Glasser; Rama K Mallampalli
Journal:  Microbes Infect       Date:  2011-09-10       Impact factor: 2.700

3.  Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.

Authors:  Matthew J Wargo; Maegan J Gross; Sathish Rajamani; Jenna L Allard; Lennart K A Lundblad; Gilman B Allen; Michael L Vasil; Laurie W Leclair; Deborah A Hogan
Journal:  Am J Respir Crit Care Med       Date:  2011-05-11       Impact factor: 21.405

Review 4.  The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections.

Authors:  SeungHye Han; Rama K Mallampalli
Journal:  Ann Am Thorac Soc       Date:  2015-05

Review 5.  Surfactant phospholipid metabolism.

Authors:  Marianna Agassandian; Rama K Mallampalli
Journal:  Biochim Biophys Acta       Date:  2012-09-29

6.  A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients.

Authors:  Ida Chiara Guerrera; Giuseppe Astarita; Jean-Philippe Jais; Dorota Sands; Anna Nowakowska; Julien Colas; Isabelle Sermet-Gaudelus; Martin Schuerenberg; Daniele Piomelli; Aleksander Edelman; Mario Ollero
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

7.  Choline Triggers Exacerbations of Chronic Obstructive Pulmonary Disease in Patients Infected with Pseudomonas aeruginosa.

Authors:  Sandra Grumelli
Journal:  Curr Respir Med Rev       Date:  2016

Review 8.  Interactions of particulate matter and pulmonary surfactant: Implications for human health.

Authors:  Feifei Wang; Jifang Liu; Hongbo Zeng
Journal:  Adv Colloid Interface Sci       Date:  2020-08-19       Impact factor: 12.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.